HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.

Abstract
Cancer vaccines designed to elicit an antibody response that target antigenic sites on a tumor antigen must closely mimic the three-dimensional structure of the corresponding region on the antigen. We have designed a complex immunogen derived from the extracellular domain of human HER-2/neu-(626-649) that represents a three-dimensional epitope. We have successfully introduced two disulfide bonds into this sequence, thereby recapitulating the natural disulfide pairings observed in the native protein. To evaluate the immunogenicity of the doubly cyclized disulfide-linked peptide versus the free uncyclized peptide we examined the induction of antibody responses in both inbred and outbred mice strains, with both constructs eliciting high titered antibodies. The disulfide-paired specific antibodies exhibited enhanced cross-reactivity to HER-2/neu expressed on BT-474 cell line as determined by flow cytometry. The antitumor activities of the disulfidepaired specific antibodies did not improve the in vitro growth inhibition of human breast cancer cells overexpressing HER-2, but showed superior antitumor responses in the context of ADCC and interferon-gamma induction. Inbred mice (FVB/n) vaccinated with the disulfide-paired epitope exhibited a statistically significant reduction in the development of exogenously administered tumors in vivo compared with mice receiving either the free uncyclized or the promiscuous T-cell epitope (MVF) control peptide (p = 0.001). This study demonstrates the feasibility and importance of designing conformational epitopes that mimic the tertiary structure of the native protein for eliciting biologically relevant anti-tumor antibodies. Such approaches are a prerequisite to the design of effective peptide vaccines.
AuthorsNaveen K Dakappagari, Kenneth D Lute, Sharad Rawale, Joan T Steele, Stephanie D Allen, Gary Phillips, R Todd Reilly, Pravin T P Kaumaya
JournalThe Journal of biological chemistry (J Biol Chem) Vol. 280 Issue 1 Pg. 54-63 (Jan 07 2005) ISSN: 0021-9258 [Print] United States
PMID15507452 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antibodies, Neoplasm
  • Cancer Vaccines
  • Disulfides
  • Epitopes, B-Lymphocyte
  • Peptide Fragments
  • Vaccines, Synthetic
  • Interferon-gamma
  • Receptor, ErbB-2
Topics
  • Amino Acid Sequence
  • Animals
  • Antibodies, Neoplasm (immunology)
  • Breast Neoplasms (immunology, therapy)
  • Cancer Vaccines (chemistry, immunology)
  • Disulfides
  • Epitopes, B-Lymphocyte (chemistry, immunology, metabolism)
  • Female
  • Humans
  • Interferon-gamma (biosynthesis, immunology)
  • Mice
  • Mice, Inbred ICR
  • Molecular Sequence Data
  • Neoplasms, Experimental (immunology, prevention & control)
  • Peptide Fragments (chemistry, immunology)
  • Protein Conformation
  • Receptor, ErbB-2 (chemistry, immunology)
  • Vaccines, Synthetic (chemistry, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: